entinostat,atezolizumab,bevacizumab
syndax pharmaceuticals,roche
['atezo', 'entinostat', 'bevacizumab', 'rcc,(-irccs),(-srcc),(-urcc)']
ph 1/2: entinostat (histone deacteylase inhibitors) + atezo/bevacizumab in mrcc ph1 dose: 5mg (gr3+ aes: 21/31 pts) orr: cohort a (no prior io)=60%; cohort b (prior io): 33% pfs: 14 months (cohort a) and 10 months (cohort b) #asco23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @MCG_Urology and @AUB_Lebanon 🇱🇧